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OBJECTIVES: Acute bleeds in CHwI patients can be managed with infusions of 
bypassing agents, such as recombinant factor VIIa (rFVIIa). Sequelae of frequent joint 
bleeding include arthropathy, pain and disability. The majority of bleeds are now 
treated at home based on physician recommendations or patient/caregiver experience. 
Consequently, actual treatment patterns and the impact of CHwI on patients and their 
families are not well understood. This study assessed the feasibility of daily collection 
of treatment outcomes as reported by CHwI patients and/or their caregivers. 
METHODS: Frequently-bleeding patients with CHwI (average of ≥4 bleeds over a 
3-month period) prescribed rFVIIa as ﬁrst-line therapy were recruited. Each day, 
patients/caregivers recorded daily activities, QoL (EQ-5D, VAS health/pain), planned 
work or school for the patient/caregiver, family assessment of anxiety/stress and activ-
ity changes via paper diary, and optional electronic interface. When acute bleeds 
occurred, they recorded symptoms, treatment decisions, and absenteeism/lost produc-
tivity. Each medication dose was recorded on an hourly grid including subjective 
status, pain score, and mixing/administration time. Treatments were veriﬁed by com-
parison of product box-tops to diaries. RESULTS: From 52 enrolled patients, 39 
patients (75%) completed diaries for a mean of 105.5 days (median:91; range:66–
180). Patient participation was facilitated by an average of 13 calls/emails per patient 
by a dedicated patient support representative. On average, 13.9% of days were bleed 
days (median:8.2%; range:0–72%). The diary captured 194 bleeding events in 38 
patients; 176 treated hemorrhages (158 rFVIIa-treated). Most bleeds were spontane-
ous (57.4%) and involved joints (69.7%). Thirty-eight patients provided QoL data 
on 3771 of 3777 eligible days. CONCLUSIONS: This study demonstrated the feasibil-
ity of daily diary completion by patients/caregivers with CHwI, providing insights into 
home treatment of CHwI and its impact on patients and their families. High comple-
tion rates were facilitated by dedicated patient support and motivated participants.
PSY45
IMPACT OF ACUTE BLEEDING AND ADMINISTRATION OF BYPASSING 
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OBJECTIVES: Patients experience acute bleeding episodes that can be managed with 
infusions of BPAs. The study aims to assess impact of hemorrhages on patient/car-
egiver daily activities, absenteeism/productivity, and time spent mixing/administering 
recombinant factor VIIa (rFVIIa) and plasma-derived activated prothrombin complex 
concentrates (pd-aPCC). METHODS: Frequently bleeding CHwI patients (≥4 bleeds 
in 3 months) prescribed rFVIIa as ﬁrst-line treatment, or their caregivers, recorded 
treatments and daily activity changes for 3–6 months including time mixing/adminis-
tering treatments. RESULTS: For 39 diary patients with 188 initial day of bleeds, 
53.7% were reported with activity unchanged, 31.9% slightly changed, 10.6% sig-
niﬁcantly rearranged, and 3.7% majorly changed for patients/caregivers. For bleed 
days 3+, 59.6% reported activity unchanged, 17.0% slightly changed, 7.0% signiﬁ-
cantly changed, and 16.4% majorly changed. On a 10-point scale, median(range) 
interference was: day 1, 2.0(0–10); day 2, 3.0(0–10); and days 3+, 4.0(0–10). Only 
230 of 491 bleeding days were patient work/school days, with 13.5% fully missed, 
3.5% partially missed, and 3.9% unproductive. Only 118 of 229 caregiver bleeding 
days were work/school days, with 9.3% fully missed, 7.6% partially missed, and 
0.8% unproductive. Of 176 BPA-treated bleeding episodes, mixing/administration 
times were reported for 1270 rFVIIa and 80 pd-aPCC injections. Median 
mixing+administration times were 5.0+5.0 min for rFVIIa and 29.0+24.5 min for 
pd-aPCC. Both mixing and administration times were signiﬁcantly shorter for rFVIIa 
(p < 0.0001). The differences were similar for both hemarthroses and muscle bleeds 
and for on-demand only patients (P < 0.0001 for all). CONCLUSIONS: Acute bleed-
ing episodes interfere with patient/caregiver/family activities. However, patients disa-
bled by frequent joint bleeds, and non-working caregivers with multiple children with 
hemophilia may confound simple analysis of work/school interference. An important 
contributor to the impact of CHwI is burden of treatment; results demonstrate a 
signiﬁcant difference per infusion between rFVIIa and pd-aPCC, which parallels the 
package insert recommendations, although limited patient sample size should be 
noted.
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EFFECT OF ACUTE BLEEDING EPISODES ON QUALITY OF LIFE (QOL) 
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OBJECTIVES: QoL assessments in frequently-bleeding CHwI patients and their fami-
lies are confounded by pre-existing arthropathy and family circumstances. Periodic 
QoL assessments typically made on non-bleed days, may not provide complete reﬂec-
tions of the burden on patients/families. This study evaluates the impact of bleeding 
episodes on patients/caregivers/families and the association between monthly QoL 
scores and patients’ average diary experience. METHODS: Frequently bleeding CHwI 
patients (≥4 bleeds in 3 months) or their caregivers, provided daily assessment of 
EQ-5D (Index, VAS), VAS-pain, and family anxiety/stress/activity change over 3–6 
months. Hierarchical models, stratiﬁcation, and comparison with mean non-bleed 
scores were used to evaluate instrument responsiveness to bleed/non-bleed 
days. RESULTS: QoL data were recorded by 37 of 39 enrolled patients/caregivers 
(3771/3777 eligible diary days, 472 bleed/3299 non-bleed days). Median (range) diary 
duration was 91 (66–180) days, with 8.2% (0–72.2%) bleed days. Median QoL 
parameters were worse (P < 0.0001) on bleed days (Bleed/Non-bleed): EQ-5D index 
(0.75/0.83), VAS (72.5/85.0), VAS-Pain (4.0/1.0), and for all EQ-5D dimensions. 
Trends held at a patient level and within hierarchical models (p < 0.001). Bleed days 
had higher (P < 0.001) proportions of days with abnormalities in family anxiety/stress 
(42% vs. 30%) and family activity changes (34 vs. 21%). Few patients/caregivers 
reported no problems on non-bleed days in EQ-5D Index (13.5%), VAS (2.7%), 
VAS-Pain (27%), family anxiety/stress (37.8%) and family activity changes (43.2%). 
For all patients and bleed types, 70.8% of bleed days had >1 QoL score >1 standard 
deviation (SD) from the patient’s mean non-bleed scores, with 30.9% reporting pain 
scores >1SD from non-bleed baseline. CONCLUSIONS: Assessment of CHwI impact 
on patient/family QoL typically includes periodic (likely non-bleed day) evaluations 
reﬂecting baseline abnormalities. However, daily assessment indicated frequent acute 
bleeds impair QoL beyond patient’s non-bleed day baseline. New approaches are 
required to assess the cumulative impact of acute bleeds during treatment intervals.
PSY47
OBESITY- AND WEIGHT-SPECIFIC HEALTH-RELATED QUALITY OF LIFE 
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OBJECTIVES: The prevalence of obesity is increasing not only in adults, but in 
children and adolescents. Health and psychosocial issues related to obesity have been 
documented to negatively impact health-related quality of life (HRQoL), which could 
affect children and adolescents differently than adults. This research reviews the litera-
ture on HRQoL instruments utilized in obese children and adolescents. METHODS: 
A systematic search strategy was used to identify published literature between 1997 
and December 2009 via PubMed and Ovid databases. The key terms included obesity, 
quality of life, health-related quality of life, questionnaires, and adolescents. RESULTS: 
A total of 20 studies were retrieved. Fourteen studies were excluded for not including 
an obesity- or weight-speciﬁc questionnaire (n = 12) and assessing the impact of 
another disease or treatment (n = 2). Five obesity- or weight-speciﬁc instruments were 
identiﬁed: Impact of Weight on Quality of Life-Lite (IWQOL-Lite), Impact of Weight 
on Quality of Life-Kids (IWQOL-Kids), Dutch Eating Behavior Questionnaire 
(DEBQ), Sizing Me Up, and Sizing Them Up. All of the instruments were developed 
for children and adolescents, except IWQOL-Lite. Cumulatively, these ﬁve instruments 
measured 17 domains. The most common domains observed in the questionnaires 
were related to Physical Functioning/Comfort, Emotional Functioning, and Social Life. 
Other domains measured were Body Esteem, Family Relations, Mealtime Challenges, 
and School Functioning. The domains that were most impactful in assessing HRQoL 
were Physical Comfort, Body Esteem, and Social Life. The primary outcome of the 
studies demonstrated poor HRQoL in obese children and adolescents. CONCLU-
SIONS: Obesity- and weight-speciﬁc HRQoL instruments are limited, especially for 
children and adolescents. With the increasing prevalence of obesity in this subpopula-
tion, there is a signiﬁcant need for the development of instruments to assess the total 
impact of this disease. The information provided from these instruments can assist 
with future obesity treatment in children and adolescents.
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OBJECTIVES: To quantify the value to patients of reducing the severity and size of 
plaque psoriasis (PsO) skin lesions. METHODS: Individuals with a self-reported 
diagnosis of PsO were recruited from a nationally representative household panel. 
Individuals completed a web-based choice-format conjoint analysis survey and were 
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asked to choose between hypothetical treatment pairs in a series of choice questions. 
Each choice alternative was deﬁned by lesion severity (redness, thickness, and texture), 
percentage of body surface area (BSA) covered by the lesions, type of treatment (oral 
agent, subcutaneous injection, or phototherapy), injection discomfort or pain (if type 
of treatment included injections), risk of serious lung infection, and monthly out-of-
pocket cost. Preference weights were estimated using mixed logit methods. Conjoint 
preference weights were used to calculate willingness-to-pay (WTP) for reductions in 
lesion severity and BSA. RESULTS: A total of 28,200 panel members were invited to 
participate in the survey. A total of 18,330 individuals responded to the invitation 
and 503 qualiﬁed to participate. A total of 419 PsO patients completed the survey; 
mean age was 54.5 years and 52% were female; 64% of patients self-reported their 
PsO severity as mild or mild-to-moderate; 12%, 12%, 7% and 3% of patients self-
reported their PsO severity as moderate, moderate-to-severe, severe, and very severe, 
respectively. Patients were willing to pay up to $486.73 per month to eliminate severe 
lesions covering 25% BSA on the arms and legs. Patients were willing to pay $429.78 
each month to eliminate severe lesions of 25% BSA on the torso. Patients were willing 
to pay $444.80 per month to eliminate moderate lesions covering 4% BSA on the 
face. CONCLUSIONS: Individuals with PsO are willing to pay more than $400 out-
of-pocket per month to reduce lesion severity and percentage of BSA covered by the 
lesions.
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OBJECTIVES: To determine impact of disease on career choices, absenteeism, and 
work loss among individuals with psoriasis (PsO). METHODS: A nationally repre-
sentative survey was conducted in Q2 2009 of PsO sufferers. Participants were ≥18 
years of age and reported their disease status as mild, moderate, and severe. Career 
choices and work productivity were assessed. Productivity was measured using the 
Work Productivity and Activity Impairment (WPAI) scale, which includes absenteeism, 
presenteeism, work productivity loss, and activity impairment. RESULTS: A total of 
1003 patients responded to the survey (mean age was 50 years, 88% were white, and 
58% were female). A higher percentage of patients with severe disease (22%) were 
disabled as compared with the moderate (15%) and mild (12%) groups. A signiﬁcantly 
higher proportion of individuals with severe disease (37%) and moderate (14%) 
reported that PsO has affected their career choice compared to those with mild disease 
(4%). Similarly, a signiﬁcantly higher percentage of individuals with severe (31%) and 
moderate (10%) disease reported that PsO affects their current career choice as com-
pared to mild disease (3%). Among the employed, on average, PsO sufferers reported 
a 4% absenteeism rate, 14% presenteeism rate, and 14% productivity loss. Activity 
impairment, regardless of employment status, was signiﬁcantly higher for the severe 
patients (54%; p < 0.05) as compared with moderate (24%) or mild (7%) sufferers. 
The severe disease group also reported signiﬁcantly higher rates of absenteeism (21%), 
presenteeism (47%), and work productivity loss (47%) than their moderate or mild 
counterparts. CONCLUSIONS: PsO is a debilitating disease which impacts multiple 
aspects of an individual’s lifestyle including career choices and physical functioning. 
Among the actively employed, moderate-to- severe PsO has a greater impact on their 
previous and current career choices as compared with patients with mild psoriasis. In 
addition, patients with severe PsO are associated with greater work loss and activity 
impairment.
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DISPARITY IN THE MANAGEMENT OF OBESITY IN AMBULATORY 
SETTING: A NAMCS 2006–07 ANALYSIS
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OBJECTIVES: Disparities in anti-obesity medication use were clearly demonstrated 
by Cawley et.al. However, the most effective interventions for obesity management 
combine nutrition education, diet and exercise counseling, with pharmacotherapy. 
Thus, the objective of this study was to identify factors associated with obesity man-
agement and identify disparities in obesity management amongst adults diagnosed 
with obesity. METHODS: The study was performed using 2006 and 2007 National 
Ambulatory Medical Care Survey, a cross-sectional visit level database. Patient visits 
(>= 18 years) with an obesity diagnosis (ICD-9-CM: 278.00) were included in the 
study. Prescription of FDA approved anti-obesity medications and/or weight reduc-
tion, exercise and diet/nutrition counseling were considered as obesity management. 
Descriptive statistics and multivariate logistic regression were conducted to identify 
disparity while adjusting for age, race, sex, region, insurance status, co-morbidity and 
MSA. RESULTS: Total 113 million visits for obesity were estimated for 2006–2007. 
Obesity management was provided in 47.84% visits, of which medication was pre-
scribed in 12% of visits. Adjusted analysis showed PCP’s were more likely to provide 
obesity management (OR—1.703 CI: 1.325–2.188) than specialists. Patients from 
non-MSA region (OR—0.614 CI: 0.455–0.829), and older patients (OR—0.986 CI: 
0.978–0.994) were less likely to receive obesity management. Patient visits that were 
covered through private insurance (OR—0.317 CI: 0.166–0.606) or public insurance 
(OR—0.297 CI: 0.160–0.552), had a lesser likelihood to receive obesity management. 
Patient visits with high co-morbid conditions were more likely to receive obesity 
management (OR—1.641 CI: 1.085–2.481). CONCLUSIONS: Specialty differences 
in obesity management were identiﬁed, one in two patients diagnosed as obese did 
not receive obesity management. This suggests that, though it is a known risk factor 
for many other chronic illnesses, physicians still fail to prioritize obesity and provide 
effective management.
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OBJECTIVES: The presence of parks and recreational areas (green spaces) in urban 
areas may facilitate increases in physical activity among urban residents and reduce 
the impact of chronic disease risk factors such as overweight and obesity. We hypoth-
esize that variable rates of obesity among major metropolitan cities in the U.S. may 
be explained by the presence of high quality green space and recreational centers. 
Speciﬁcally, that parks acres and total park expenditures will predict levels of obesity. 
We also hypothesize that the presence of recreational centers will explain variable 
levels of obesity. If the presence of quality parks in urban areas is associated with 
lower obesity prevalence, this provides evidence for policy recommendations to reduce 
the adverse effects of obesity and overweight. METHODS: City park data for the year 
2007, was linked to Behavioral Risk Factor Surveillance System SMART data from 
2007 urban responses of physical activity and obesity. The total park acreage, park 
expenditures, and recreational centers per capita were obtained from The Trust for 
Public Land. Step wise linear regression modeling was used to test our hypotheses. 
RESULTS: Overall, the model signiﬁcantly predicted Obesity Prevalence, with both 
Percent Parkland and Park Expenditures accounting for 30% of the variation in 
Obesity Prevalence [R2+0.299, F(2.47) = 10.03, p < 0.001]. Additionally, a moderate 
effect size was found for the relationship between Percent Obesity and both Percent 
Parkland and Park Expenditures (R2 = −0.34, and −0.40 respectively). Once entered 
in the second step, Recreational Centers explained no additional variance [R2 = 0.299, 
F(3.46) = 6.55, p < 0.1001]. CONCLUSIONS: Obesity prevalence is moderately 
explained by Percent Parkland and Park Expenditures. These ﬁndings have direct 
policy implications, and show that both quality and access to parks are public health 
initiatives that may be used to promote healthier communities.
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INTRAGASTRIC BALOON (IGB) FOR MORBIDLY OBESE (MOP) AND 
SUPER OBESE PATIENTS (SOP) : SYSTEMATIC REVIEW (SR) AND 
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OBJECTIVES: To compile the body of evidence and produce a HTA on IGB in 
morbidly obese (MOP) and super obese (BMI ≥ 50) patients. To evaluate the impact 
on IGB on weight loss, co-morbidities (CM), reduction of post-operatory complications 
on bariatric surgery. METHODS: We performed a SR on Medline and Cochrane 
Library among other databases, including articles published until January 2010. We 
searched “Gastric Balloon[Mesh]”, “intragastric balloon”, “Comparative Study [Pub-
lication Type]”, “Randomized Controlled Trial [Publication Type]”, “random*” e 
“systematic[sb]”. RESULTS: We found two SR without meta-analysis (MA), two SR 
with MA and two randomized controlled clinical trials (RCCT). In MOP the use of 
IGB does not improve the weight loss compared to diet (Level of Evidence 1b). There 
are no long term efﬁcacy data available and there might be a weight gain after the 
IGB is withdrawn. The risk of minor complications (gastric ulcer and abdominal pain) 
but not of major complications (intestinal obstruction and esophageal laceration) is 
greater in patients using IGB (LE 1b). For SOP there is insufﬁcient evidence to support 
that the use of IGB before bariatric surgery reduces the conversion rate from laparo-
scopic to open surgery or the intra-operatory complication risks (LE 4). There is a 
lack of evidence on the impact of IGB use on CM such as diabetes, hypertension or 
sleep apnea for both MOP and SOP. CONCLUSIONS: For MOP there is evidence 
that the use of IGB does not lead to greater weight loss compared to diet and it 
increases the risk of minor complications (LE 1b). For SOP there is insufﬁcient evidence 
of effectiveness and safety to support the use of IB as a previous step before gastric 
bypass surgery. For both, there is a lack of evidence on the impact of IGB on CM.
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OBJECTIVES: Musculoskeletal pain is experienced by more than a third of the adult 
population. Alleviation of pain is an important aspect of care in these patients. The 
aim of the present study was to assess the number of NSAID prescriptions prescribed 
to patients with musculoskeletal pain during 2004–2008 at 4 primary health care 
centres in Sweden. METHODS: This retrospective longitudinal study was based on 
primary care electronic medical records review and data for patients with any ICD 
diagnosis code of musculoskeletal pain and prescription of any ATC code for NSAID, 
